The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.

Breast Cancer Research and Treatment
G F P AleixoG R Williams

Abstract

Body composition metrics as predictors of adverse events are a growing area of interest in oncology research. One barrier to the use of these metrics in clinical practice is the lack of standardized cut points for identifying patients with at-risk body composition profiles. We examined the association of chemotherapy adverse events with several body composition measures, using alternative cut points from published studies. This is a retrospective study of women diagnosed with early breast cancer (EBC). Axial computerized tomography (CT) images from lumbar L3 segments were analyzed for the following body composition measures: myosteatosis (low Skeletal Muscle Density/SMD), sarcopenia (low Skeletal Muscle Index/SMI), and high Visceral Adipose Tissue (VAT). Adverse events during chemotherapy were dose reduction, early treatment discontinuation, and hospitalization. Log-binomial modeling was used to evaluate associations between body composition measures at different cut points with adverse events, adjusting for age, race, Body Mass Index/BMI, and comorbidities. Relative risks were reported as the measure of association. In a sample of 338 women, mean age was 51, 14% were age 65 or older, 32% were non-white, 40% had obesity (/BMI ≥...Continue Reading

References

May 1, 1997·The Journal of Nutrition·I H Rosenberg
Jun 16, 2005·Archives of Internal Medicine·Jennifer J GriggsGary H Lyman
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carla M M PradoMichael B Sawyer
Nov 28, 2012·Journal of Oncology Practice·Gary H Lyman
Mar 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lisa MartinVickie E Baracos
Apr 15, 2015·Gynecologic Oncology·Neil S Horowitz, Alexi A Wright
Dec 17, 2015·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Lindsey A TorreAhmedin Jemal
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Feb 18, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shlomit Strulov ShacharTomohiro F Nishijima
Jul 6, 2016·Frontiers in Endocrinology·Mark W HamrickDanielle M Frechette
Nov 5, 2016·The Breast : Official Journal of the European Society of Mastology·Hánah N RierMark-David Levin
Feb 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shlomit Strulov ShacharHyman B Muss
Aug 29, 2017·Journal of Geriatric Oncology·Grant R WilliamsShlomit Strulov Shachar
Sep 28, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Elise DelucheNicole Tubiana-Mathieu
Apr 17, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Elisa GobbiniSuzette Delaloge
May 26, 2018·Cancer·Candyce H KroenkeBette J Caan
Jun 30, 2018·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·O Abdel-Rahman
Oct 23, 2018·Journal of Geriatric Oncology·Grant R WilliamsShlomit S Shachar
Jul 12, 2019·Breast Cancer Research and Treatment·G F P AleixoS S Shachar
Aug 2, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elizabeth M Cespedes FelicianoBette J Caan
Dec 27, 2019·Critical Reviews in Oncology/hematology·G F P AleixoG R Williams
Feb 1, 2020·Current Treatment Options in Oncology·Federico Bozzetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.